5-Amino-1MQ vs MOTS-c: Two 'Metabolic' Compounds, Honestly Compared

5-Amino-1MQ and MOTS-c get sold side by side in the same research-chemical corners of the internet, pitched at the same audience with nearly the same promise: better metabolism, more fat burning, a body that runs cleaner. They sound like cousins. They are not — one is a small molecule and one is a true peptide, and their mechanisms have almost nothing in common. What they do share is the single fact that matters most, and it's worth saying before we compare anything else.

The honest headline: both 5-Amino-1MQ and MOTS-c rest on genuinely interesting biology and real preclinical data, and neither has a single controlled human trial proving it does what it's marketed to do. 5-Amino-1MQ is an NNMT-inhibiting small molecule with mouse-only obesity data. MOTS-c is a mitochondrial-derived peptide with striking rodent endurance data and some human observational data — but no interventional human performance trial. Both are unapproved, sold grey-market, and unverified for identity, dose, and purity. Hold that shared frame against every difference below.

What Each One Actually Is

The first thing to get straight is that these are different kinds of molecule, which the marketing blurs by lumping them together.

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule, membrane-permeable inhibitor of the enzyme NNMT — nicotinamide N-methyltransferase¹. It is not a peptide at all, despite where it's sold. NNMT consumes nicotinamide (a vitamin-B3 form your body recycles into NAD⁺) and methylates it for disposal; the idea is that blocking NNMT preserves nicotinamide, frees up methyl groups, and pushes fat cells toward burning more fuel. It's taken as an oral capsule.

MOTS-c (Mitochondrial Open reading frame of the Twelve-S rRNA type-c) is a genuine peptide — and an unusual one, encoded not in your nuclear DNA but inside your mitochondria's 12S ribosomal RNA gene, making it a "mitochondrial-derived peptide"³. It behaves like a metabolic regulator: in mice it targets skeletal muscle, activates the AMPK energy-sensing pathway, promotes glucose uptake, and protects against diet-induced obesity and insulin resistance³. It's injected.

So already the picture diverges: an oral small-molecule enzyme inhibitor versus an injectable mitochondrial signaling peptide. Same shelf, different biology.

The Evidence — Both Strong in Animals, Both Empty in Humans

This is where the comparison gets honest, because the two compounds land in almost exactly the same evidence tier despite their different mechanisms.

5-Amino-1MQ's case is entirely rodent. The foundational 2014 finding showed that knocking down NNMT protected mice from diet-induced obesity, increasing energy expenditure in fat and liver². Then a 2018 study reported that selective, membrane-permeable small-molecule NNMT inhibitors — the 5-amino-1MQ chemical class — reversed diet-induced obesity in mice¹. That is the single most-cited justification sellers point to, and it is real. But notice the species line: mouse, mouse, mouse. There is no published controlled human trial showing 5-Amino-1MQ produces fat loss, raises NAD⁺, or builds muscle in people.

MOTS-c's case is stronger on paper but has the same fatal gap. The landmark 2021 study showed MOTS-c is an exercise-induced regulator of age-dependent physical decline, and that injecting it into mice improved their running performance, especially in aged animals⁴. MOTS-c also has something 5-Amino-1MQ does not: real human data. But that human data is observational — circulating MOTS-c levels track with fitness and metabolic conditions; researchers have measured it during exercise interventions in obese men⁵. Observing that fit people have different MOTS-c levels is a world away from showing that injecting it improves performance. No controlled interventional human trial exists for MOTS-c either.

Read together, both compounds occupy the "it worked in animals, it's untested in humans" tier. MOTS-c is one rung higher only because it adds human correlation — and correlation is not proof. Mouse-to-human translation in metabolism is notoriously unreliable; the history of the field is littered with compounds that melted fat off mice or made them run farther and then did nothing in people.

Where They Differ, and Where It Stops Mattering

The differences are real and worth naming. 5-Amino-1MQ is oral, a small molecule, and its story is purely about fat loss and NAD⁺. MOTS-c is injected, a true peptide, and its story is about endurance and exercise-mimicry (with metabolic benefits underneath). If you only read mechanism pages, they look like tools for different jobs.

But the differences stop mattering at the point that counts for a buyer. Neither is FDA-approved for any indication. Both are sold as grey-market "research chemicals," typically labeled "not for human consumption" or "for research use only" — meaning no regulator verifies what's in the capsule or the vial, at what dose, free of contaminants. That sourcing problem is an independent safety concern layered on top of the missing efficacy data, and it applies identically to both. For MOTS-c there's an additional wrinkle for tested athletes: a peptide explicitly marketed to enhance physical capacity is exactly the kind of compound anti-doping authorities scrutinize. 5-Amino-1MQ's fat-loss framing is less directly performance-coded, but a drug-tested athlete should verify the status of anything in this category before going near it.

If your actual goal is body composition rather than a science experiment, our honest guide to peptides for fat loss walks through how often these mechanistic stories fail to deliver in controlled human studies. For the deeper single-compound breakdowns, see our full reviews of 5-Amino-1MQ and MOTS-c — and for the doses circulating in the community (none of them validated by human trials), the 5-Amino-1MQ dosage page.

Bottom Line

5-Amino-1MQ and MOTS-c are sold as if they were interchangeable metabolic upgrades. They aren't interchangeable — one is an oral small-molecule NNMT inhibitor aimed at fat loss, the other an injectable mitochondrial peptide aimed at endurance — but they are equivalent in the one way that should drive your decision: neither has a controlled human trial proving it works for the goal it's marketed for.

5-Amino-1MQ's evidence is mouse-only. MOTS-c's is rodent-plus-human-correlation, which is a slightly higher tier but still not interventional proof. Both are unapproved, grey-market, and unverified. The honest verdict is that these are two promising research molecules and two reasonable trial candidates — not two proven human compounds, and certainly not a choice between two things that "work." Treat any confident "this one did it for me" claim as unproven anecdote until human trials exist. For where both rank against the rest of the field, and the research tools and calculators we use to keep the claims honest, start there before you start anywhere.